Minimal residual disease combined with radiological tumor volume as a tool for identification of resected NSCLC patients at high risk of recurrence.

Michela Verzè^1,2, Roberta Minari¹, Paola Bordi¹, Giovanni Bocchialini³, Gianmarco Martines², Monica Pluchino^1,2, Simona D'Agnelli^1,2, Letizia Gnetti⁴, Agnese Cosenza¹, Valeria Balestra³, Luca Ampollini^2,3, Ludovica Leo², Gianluca Milanese^2,5, Camilla Roberti^2,5, Clarissa Gallani², Jim Hayes⁶, Umberto Malapelle⁷, Marcello Tiseo^1,2

¹Medical Oncology Unit, University Hospital of Parma, Italy.

²Department of Medicine and Surgery, University of Parma, Italy.

³Thoracic Surgery Unit, University Hospital of Parma, Italy.

⁴Pathology Unit, University Hospital of Parma, Italy.

⁵Radiological Unit, University Hospital of Parma, Italy.

⁶Guardant Health, San Francisco, CA, USA.

⁷Department of Public Health, University of Naples Federico II, Naples, Italy.

PubMed PMC DOI PDF

Abstract

INTRODUCTION: Circulating tumor DNA (ctDNA) is a valuable tool for assessing minimal residual disease (MRD) and predicting recurrence in resected non-small cell lung cancer (NSCLC) patients. Combining ctDNA-detection with radiological tumor volume may improve risk stratification. METHODS: Patients with stage I-III resectable NSCLC were prospectively enrolled in the RESIDUAL study. Plasma samples…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.